Albumin
is widely used in pharmaceutical applications to alter
the pharmacokinetic profile, improve efficacy, or decrease the toxicity
of active compounds. Various drug delivery systems using albumin have
been reported, including microparticles. Macroaggregated albumin (MAA)
is one of the more common forms of albumin microparticles, which is
predominately used for lung perfusion imaging when labeled with radionuclide
technetium-99m (99mTc). These microparticles are formed
by heat-denaturing albumin in a bulk solution, making it very challenging
to control the size and dispersity of the preparations (coefficient
of variation, CV, ∼50%). In this work, we developed an integrated
microfluidics platform to create more tunable and precise MAA particles,
the so-called microfluidic-MAA (M2A2). The microfluidic chips, prepared
using off-stoichiometry thiol-ene chemistry, consist of a flow-focusing
region followed by an extended and water-heated curing channel (85 °C).
M2A2 particles with diameters between 70 and 300 μm with CVs
between 10 and 20% were reliably prepared by adjusting the flow rates
of the dispersed and continuous phases. To demonstrate the pharmaceutical
utility of M2A2, particles were labeled with indium-111 (111In) and their distribution was assessed in healthy mice using nuclear
imaging. 111In-M2A2 behaved similarly to 99mTc-MAA, with lung uptake predominately observed early on followed
by clearance over time by the reticuloendothelial and renal systems.
Our microfluidic chip represents an elegant and controllable method
to prepare albumin microparticles for biomedical applications.